1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Antibody Drugs: Technologies and Global Markets

Antibody Drugs: Technologies and Global Markets

  • September 2017
  • 115 pages
  • ID: 801344


Table of Contents

• The global market for antibody drugs reached $80.8 billion in 2016. The market should reach $114.6 billion by 2022 increasing from $84.5 billion in 2017, at a compound annual growth rate (CAGR) of 6.3% from 2017 through 2022.
• The global antibody drugs market for autoimmune diseases reached $37.3 billion in 2016. The market should reach $48.1 billion by 2022 increasing from $37.5 billion in 2017, at a CAGR of 5.1% from 2017 through 2022.
• The global antibody drugs market for lymphoma reached $37.3 billion in 2016. The market should reach $48.1 billion by 2022 increasing from $37.5 billion in 2017, at a CAGR of 5.1% from 2017 through 2022.
Chapter 1: Introduction
Study Goals and Objectives
Monoclonal antibodies are a type of bioengineered protein drugs. These drugs are widely used in the treatment of a variety of chronic diseases such as cancer; autoimmune diseases such as multiple sclerosis; rheumatoid arthritis; cardiovascular diseases; and other diseases such as asthma, osteoporosis, etc. BCC Research’s goal in conducting this study is to provide an overview of the current and future global market for antibody drug products.

This report explores the present and future strategies of the companies in the antibody drug product market, which includes murine mAbs, chimeric mAbs, human mAbs and humanized mAbs. The holdups and the needs of the market are discussed in this report. The classifications, comparisons and usage of these products are also portrayed in this report.

A detailed analysis of the antibody drug product industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period of 2017 through 2022.

Applications for antibody drug products are also discussed. The report also covers significant patents and their allotments in each product category.

Reasons for Doing This Study
The antibody drug industry is one of the fast -growing industries in the pharmaceutical sector. A reason for this is that these drugs have fewer side effects than chemical drugs. Various biopharmaceutical companies are making their way into the antibody protein drug market. Manufacturing companies are focusing on the production of protein drugs. Antibody drug products have become important part of the biomedical industry.

The pharmaceutical industry is undergoing a change from chemical drugs to protein drugs due to their high specificity, enhanced efficacy, affinity, solubility and low toxicity. R&D spending, increasing competition and evolving technologies are providing a new direction to the market. This study looks at the systems affected by these trends.

Companies’ acquisition strategies and collaborative agreements are also covered in this report. This study also discusses the strength and weaknesses of each type of monoclonal antibody in light of the new technologies, growing competition and changing customer needs.

Scope of Report
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.

BCC Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.

The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.

Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.

Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.

Information Sources
Many companies were surveyed to obtain data for this study, including were manufacturers and end users of antibody drug products. Data was gathered from various industry sources. BCC Research spoke with industry officials and consulted newsletters, company literature, product literature, technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.

Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive search of literature, which included technical newsletters, journals and other sources. Data were collected through interviews and correspondence with manufacturers and users of antibody drugs. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:

The U.S.

• All countries

Emerging markets
• China
• India
• Japan
• Korea
• Taiwan
• Africa
• Australia
• New Zealand
• Canada

Antibody Drugs, by Type
Murine mAbs
Chimeric mAbs
Human mAbs
Humanized mAbs

Antibody Drugs, by Application
Autoimmune diseases
Solid tumor
Lymphomas and leukemia
Others (asthma, osteoporosis, cardiovascular diseases)

Chapter 2: Summary and Highlights 
Antibody drugs are created through the use of modern scientific techniques such as genetic engineering and recombinant deoxyribonucleic acid (DNA) technology. They are produced by living cells and organisms such as Escherichia coli (E. coli), yeast, mammalian cells, etc. 

These protein drugs have gained in significance due to the increase in the number of chronic diseases such as asthma, multiple sclerosis and arthritis, and fatal diseases such as cancer and cardiovascular diseases. The antibody drug industry has grown globally due to its pivotal role in the treatment of life-threatening diseases. 
This report analyzes and assesses the therapeutic applications of antibodies such as mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agent s, such as antibody drug conjugates. 
Genetic engineering technology has made it possible to produce these protein molecules with modified features. Owing to its high specificity and low immunogenicity, protein therapeutics is widely used to treat various life-threatening diseases such as cancer, diabetes and multiple sclerosis. Increasing R&D , increasingly sedentary lifestyles, increasing incidence of various diseases and the growing population of baby-boomers are the driving forces for the monoclonal antibody market. 
Leading manufacturers of mAbs include F. Hoffmann -La Roche Ltd., Johnson & Johnson Inc., Novartis 
AG, Biogen Inc., Amgen Inc., Merck KGaA, Seattle Genetics Inc. and Abb V ie Inc. More and more novel antibody drugs are being investigated and developed due to advances in technology. 

Approaches such as the development of antibody drug conjugates and bi -specific antibodies that attack the proteins present inside a cancerous cell are the present-day outlook of R&D of therapies. These therapies suppress the further progression of diseases such as arthritis, multiple sclerosis, hepatitis, Crohn’s 
The market for antibody drugs is divided into four types of diseases: autoimmune diseases, solid tumors, lymphoma and leukemia and other diseases such as asthma, rheumatoid arthritis and osteoporosis. 
In 2016, antibody drugs had the largest share of the market in autoimmune diseases with approximately 46.1%e and shares of the markets for solid tumors, lymphoma and leukemia, and other diseases of 24.2%, 13.2% and 16.5%, respectively. When BCC Research looked at the 2013 markets in its previous report on this subject, those market shares were 44.1%, 27.7%, 10.4% and 17.8%, respectively.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
TNF Inhibitors - A Pipeline Analysis Report

TNF Inhibitors - A Pipeline Analysis Report

  • $ 3500
  • Industry report
  • October 2017
  • by Infiniti Research Limited

TNF Inhibitors: An insightThe TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global ...

Kaposi Sarcoma Global Clinical Trials Review, H2, 2017

Clinical Research in Kaposi Sarcoma in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Kaposi Sarcoma Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Kaposi Sarcoma Global Clinical Trials Review, H2, 2017" provides an overview of Kaposi Sarcoma clinical ...

Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Global Clinical Trials Review, H2, 2017

Clinical Research in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Global Clinical ...

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the US - Forecast

  • January 2018
    28 pages
  • Anti-Infective  

    Antibiotic Resi...  


  • United States  

View report >

Diabetes and Cardiovascular Disease Statistics in the US

  • January 2018
    19 pages
  • Diabetes  

    Cardiovascular ...  


  • United States  

View report >

Therapy Market in the US

  • December 2017
    10 pages
  • Therapy  

  • United States  

    United Kingdom  

View report >

Related Market Segments :

Monoclonal Antibody


Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.